Definium Therapeutics Cash Flow Statement
NASDAQ: DFTXHealthcareBiotechnologyUSD
36.90+2.72 (+7.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Definium Therapeutics free cash flow
In fiscal 2025, Definium Therapeutics generated -$131.6 million of operating cash flow. That left free cash flow of -$131.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M | -33.94M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Stock-Based Compensation | 20.10M | 16.91M | 15.18M | 13.71M | 42.72M | 7.41M |
| Change in Working Capital | 9.45M | -3.36M | 7.38M | -2.73M | 3.75M | -1.07M |
| Operating Cash Flow | -131.56M | -79.13M | -64.36M | -50.14M | -45.82M | -23.60M |
| Investing Cash Flow | -151.61M | 0 | — | — | -297.00K | — |
| Financing Cash Flow | 267.27M | 253.20M | 21.85M | 59.05M | 98.82M | 96.70M |
| Net Change in Cash | -15.90M | 174.04M | -42.44M | 8.60M | 53.45M | 73.39M |
| Free Cash Flow | -131.56M | -79.13M | -64.36M | -50.14M | -45.82M | -23.60M |
This table shows 6 annual periods of Definium Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 8 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow DFTX's reporting calendar. What is a cash flow statement?